AstraZeneca Presents New Research on Respiratory and Immune Diseases at ATS 2024

AstraZeneca is poised to present groundbreaking clinical and real-world data at the upcoming American Thoracic Society (ATS) International Conference in San Diego, CA, from May 17-22, 2024. The pharmaceutical giant will unveil 59 abstracts, with 12 being late-breaking posters, focusing on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA), among other chronic respiratory diseases.

Sharon Barr, Ph.D., Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, remarked that the data to be presented underscores the company’s progress in developing new treatments aimed at disease modification, remission, and ultimately, a cure. Particularly for COPD patients who have limited options if their condition is uncontrolled on inhaled medicines, the results of the COURSE Phase IIa study exploring tezepelumab are promising.

Ruud Dobber, Ph.D., Executive Vice President and President of BioPharmaceuticals Business Unit at AstraZeneca, emphasized the company's commitment to transforming respiratory care through its robust pipeline of inhaled and biologic medicines. COPD, one of the leading causes of death globally, will be a significant focus, with key data underscoring the need to address cardiopulmonary risk in COPD patients and the potential of their inhaled triple therapy, BREZTRI, to mitigate this risk.

Key highlights of AstraZeneca's data at ATS 2024 include:

COPD Care Innovations:
- TEZSPIRE® (tezepelumab): Extending beyond severe asthma to target thymic stromal lymphopoietin (TSLP) and tozorakimab to reduce excess inflammation and epithelial remodeling in IL-33 driven diseases.
- COURSE Phase IIa Trial: This trial investigates tezepelumab in moderate to very severe COPD patients, including those irrespective of inflammatory drivers, baseline blood eosinophil levels, emphysema, chronic bronchitis, and smoking status.
- Tozorakimab: New mechanistic data exploring its ability to inhibit IL-33ox biological effects and block the RAGE-EGFR pathway compared to other IL-33 antibodies.

Inhaled Triple Therapy BREZTRI:
- ETHOS Phase III Trial: A post-hoc analysis exploring the effect of BREZTRI on various cardiopulmonary outcomes.
- SKOPOS-MAZI Retrospective Analysis: Real-world evidence comparing mortality rates between patients starting therapy with BREZTRI single inhaler triple therapy (SITT) versus multiple inhaler triple therapy (MITT).
- EXACOS-CV Multi-Country Study: Examining the risk of serious cardiovascular events or death following a COPD exacerbation across eight countries.

Asthma Treatment Advancements:
- AIRSUPRA® (albuterol-budesonide): A first-in-class anti-inflammatory rescue therapy for asthma in the US.
- MANDALA Phase III Post-hoc Analysis: New efficacy data of as-needed AIRSUPRA by baseline blood eosinophil count in patients with moderate-to-severe asthma.
- ACADIA Trial Design: Innovative study design approaches for investigating AIRSUPRA in adolescents.

Early Pipeline Innovations:
- AZD8630/AMG 104: An inhaled TSLP inhibitor for moderate-to-severe asthma.
- AZD4604: An inhaled, small molecule selective JAK1 inhibitor for moderate-to-severe asthma, comparing JAK selectivity and clinical implications to other marketed JAK inhibitors.

Other Presentations:
- MANDARA Phase III Trial for EGPA: Significant results showcasing the impact of FASENRA® (benralizumab) in reducing or eliminating oral glucocorticoid use in patients with EGPA.

AstraZeneca's participation in the ATS 2024 conference demonstrates its ongoing dedication to revolutionizing respiratory care through innovative treatments and comprehensive clinical trials. The extensive data presented will provide new insights into the efficacy and safety of their cutting-edge therapies, potentially offering new hope to patients suffering from chronic respiratory diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!